Stock Under 20 Picks Based on Artificial Intelligence: Returns up to 35.32% in 3 Days

Stock Under 20 Picks

This forecast is part of the Stocks Under 20 Dollars Package, as one of I Know First’s forecast services. The full package includes daily stock predictions for a total of 20 Stock Under 20 Picks stocks with bullish and bearish signals:

  • Top 10 stocks for the long position
  • Top 10 stocks for the short position

Package Name: Stocks Under 20 Dollars
Recommended Positions: Long & Short
Forecast Length: 3 Days (10/28/2018 – 10/31/2018)
I Know First Average: 3.19% (Long) & 1.56% (Short)
Stock Under 20 Picks

During the 3 Days forecast, the algorithm had predicted high returns for those seeking stock advice. The best performance in the short position came from CLVS which registered a return of 35.32%. For the long positions the largest growth was registered by KEM with a return of 33.78%, during the same period. The package itself, had an overall average return of 3.19%, in the long position, providing a premium of 1.19% over the SP500’s return of 2.00%. With regards to the short position, the package had an overall average return of 1.56%, providing investors with a premium of -0.44% over S&P500’s return of 2.00%. The I Know First’s Stock Market Algorithm accurately forecasted 6 out of 10 stocks, for the long position, and 6 out of 10 stocks, for the short position for this 3 Days forecasted period.

Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Its commercial product Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP), inhibitor of PARP1, PARP2 and PARP3 approved in the United States by the Food and Drug Administration (FDA), as monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

How to interpret this diagram:

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.